# Korro Bio

Type: Company (KRRO)

Source: Startup Intelligence Brief — https://getstartupbrief.com/entity/korro-bio
Canonical HTML page: https://getstartupbrief.com/entity/korro-bio

## Timeline

- **2026-03-09**: $85M Private Placement — Company announces oversubscribed funding to accelerate clinical trials.
- **2024-Q3**: Platform Validation — Preclinical data for lead AATD program shows high editing efficiency.
- **2023-11-01**: Merger Completion — Korro Bio becomes a public entity via merger with Freeline Therapeutics.

## Recent coverage (1 stories)

### Korro Bio Secures $85M in Oversubscribed PIPE to Advance RNA Editing Pipeline
2026-03-09 12:52:49 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Korro Bio has announced an oversubscribed $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. This capital injection is expected to extend the company's cash runway and accelerate the clinical development of its lead programs targeting genetic diseases.
Full story: https://getstartupbrief.com/story/korro-bio-85-million-private-placement-funding

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getstartupbrief.com/guides/methodology for the full editorial methodology.